Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 4 (April)

1. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
   Eur J Cancer, 43(6): 974-8. [Abstract] [Full-text]
2. Hypereosinophilic syndrome and molecularly targeted therapy.
   Semin Hematol, 44(2): S4-S16. [Abstract] [Full-text]
3. Role of imatinib-sensitive tyrosine kinases in the pathogenesis of chronic myeloproliferative disorders.
   Semin Hematol, 44(2): S17-30. [Abstract] [Full-text]
4. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
   Blood, 109(8): 3470-8. [Abstract] [Full-text]
5. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
   Blood, 109(8): 3496-9. [Abstract] [Full-text]
6. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
   Blood, 109(8): 3207-13. [Abstract] [Full-text]
7. Cancer drug resistance: The central role of the karyotype.
   Drug Resist Updat. [Abstract] [Full-text]
8. Y253H mutation appearing in a mu-BCR-ABL (e19a2) CML.
   Leuk Res. [Abstract] [Full-text]
9. Macrophages and their products in rheumatoid arthritis.
   Curr Opin Rheumatol, 19(3): 289-95. [Abstract] [Full-text]
10. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.
    J Biol Chem, 282(15): 10922-34. [Abstract] [Full-text]
11. Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract.
    Amino Acids, 32(3): 395-400. [Abstract] [Full-text]
12. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
    Am J Hematol, 82(5): 394-5. [Abstract] [Full-text]
13. Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases.
    Cancer Lett, 250(2): 329-38. [Abstract] [Full-text]
14. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Oncogene, 26(17): 2445-58. [Abstract] [Full-text]
15. Metastatic duodenal GIST: role of surgery combined with imatinib mesylate.
    Int Semin Surg Oncol, 4: 9. [Abstract] [Full-text]
16. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Mol Cancer Ther, 6(4): 1400-5. [Abstract] [Full-text]
17. Expression analysis of PCNA gene in chronic myelogenous leukemia--combined application of siRNA silencing and expression arrays.
    Leuk Res, 31(5): 661-72. [Abstract] [Full-text]
18. Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not".
    BMC Nephrol, 8: 6. [Abstract] [Full-text]
19. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.
    Eur J Haematol, 78(5): 417-31. [Abstract] [Full-text]
20. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.
    Eur J Haematol, 78(5): 389-98. [Abstract] [Full-text]
21. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
    J Am Acad Dermatol, 56(5): S68-72. [Abstract] [Full-text]
22. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.
    Leuk Res, 31(5): 691-4. [Abstract] [Full-text]
23. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.
    Clin Cancer Res, 13(8): 2463-70. [Abstract] [Full-text]
24. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Clin Cancer Res, 13(8): 2369-77. [Abstract] [Full-text]
25. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hum Pathol, 38(5): 679-87. [Abstract] [Full-text]
26. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.
    Cancer Res, 67(8): 3759-66. [Abstract] [Full-text]
27. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
    J Neurooncol, 83(1): 53-60. [Abstract] [Full-text]
28. Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas.
    Mod Pathol, 20(5): 562-9. [Abstract] [Full-text]
29. An in vitro cytologic assay for evaluation of the KIT signaling pathway in gastrointestinal stromal tumors.
    Mod Pathol, 20(5): 579-83. [Abstract] [Full-text]
30. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Blood, 109(9): 4006-15. [Abstract] [Full-text]
31. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.
    Blood, 109(9): 3676-8. [Abstract] [Full-text]
32. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.
    Blood, 109(9): 4016-9. [Abstract] [Full-text]
33. Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment.
    Best Pract Res Clin Haematol, 20(2): 311-27. [Abstract] [Full-text]
34. Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
    Best Pract Res Clin Haematol, 20(2): 125-54. [Abstract] [Full-text]
35. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.
    Int Ophthalmol, 27(1): 43-4. [Abstract] [Full-text]
36. Clinical, radiological, and pathological findings in four children with gastrointestinal stromal tumors of the stomach.
    Pediatr Hematol Oncol, 24(3): 209-19. [Abstract] [Full-text]
37. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients.
    Cancer Genet Cytogenet, 174(2): 132-7. [Abstract] [Full-text]
38. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Cancer Genet Cytogenet, 174(2): 111-5. [Abstract] [Full-text]
39. Distinguishing gastrointestinal stromal tumors from their mimics: an update.
    Adv Anat Pathol, 14(3): 178-88. [Abstract] [Full-text]
40. The anticancer drug imatinib induces cellular autophagy.
    Leukemia, 21(5): 936-42. [Abstract] [Full-text]
41. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
    Leukemia, 21(5): 926-35. [Abstract] [Full-text]
42. p210(BCR-ABL) reprograms transformed and normal human megakaryocytic progenitor cells into erythroid cells and suppresses FLI-1 transcription.
    Leukemia, 21(5): 917-25. [Abstract] [Full-text]
43. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
    Br J Haematol, 137(4): 297-306. [Abstract] [Full-text]
44. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Nat Rev Cancer, 7(5): 345-56. [Abstract] [Full-text]
45. Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model.
    Oligonucleotides, 17(1): 22-34. [Abstract] [Full-text]
46. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Expert Opin Investig Drugs, 16(5): 679-87. [Abstract] [Full-text]
47. Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib.
    Pharmacotherapy, 27(5): 775-7. [Abstract] [Full-text]
48. Activation of Abl by Helicobacter pylori: a novel kinase for CagA and crucial mediator of host cell scattering.
    Gastroenterology, 132(4): 1309-19. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.